According to a recent study researchers say, Montelukast, a leukotriene-receptor antagonist (leukotrienes mediate inflammation in the body and play a role in allergic reactions), decreased incidents of asthma in young children by about 32 percent while also reducing corticosteroid use .
Researchers conducted a one-year study involving 549 children from 68 sites in 23 countries. In the study, 278 of the children received low-dose montelukast once a day for 12 months while 271 of the children received a placebo. Results showed exacerbation of asthma occurred 1.6 times per patient per year in those taking montelukast compared with 2.24 incidents per patient per year in the placebo group.The study also showed an overall corticosteroid use was cut by 32 percent in those who took Montelukast, and inhaled corticosteroid use decreased by 40 percent.
In conclusion researchers say, that montelukast shouldn't be used the whole year round instead, the medication should be reserved more for seasonal use .